XTL Bio returns to Nasdaq

– XTL’s lead product is a treatment of multiple myeloma, and it is readying a clinical trial for the product. – / By Gali Weinreb /  XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB); TASE:XTL) More...